Press coverage about VIVUS (NASDAQ:VVUS) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. VIVUS earned a news impact score of 0.22 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.26126761029 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
VIVUS (VVUS) traded down $0.02 during mid-day trading on Friday, reaching $0.51. The company’s stock had a trading volume of 370,529 shares, compared to its average volume of 701,480. The company has a debt-to-equity ratio of 643.86, a quick ratio of 7.09 and a current ratio of 7.47. The company has a market capitalization of $53.62, a P/E ratio of 1.49 and a beta of 0.80. VIVUS has a 12-month low of $0.48 and a 12-month high of $1.38.
VIVUS (NASDAQ:VVUS) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.07. The firm had revenue of $15.19 million during the quarter, compared to the consensus estimate of $16.00 million. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. The business’s revenue was up 13.8% compared to the same quarter last year. During the same period last year, the company earned ($0.09) earnings per share. equities analysts forecast that VIVUS will post -0.32 EPS for the current fiscal year.
VVUS has been the subject of a number of research reports. ValuEngine upgraded VIVUS from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Zacks Investment Research downgraded VIVUS from a “buy” rating to a “hold” rating in a report on Saturday, January 6th.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact VIVUS (VVUS) Stock Price” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/14/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-vivus-vvus-stock-price.html.
VIVUS Company Profile
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.